Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medicamen Biotech Limited (MEDICAMEQ.NS)
INR236.85
+3.75 (+1.61%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
1506, Chiranjiv Tower 110019
New Delhi, IN
New Delhi, IN
CEO
Rajesh Madan Pharma
Website
medicamen.com
IPO
2021-10-27
ISIN INE646B01010
Also trades on
Bombay Stock Exchange · MEDICAMEQ.BO (INR)
National Stock Exchange of India · MEDICAMEQ.NS (INR)
Description
Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR236.85
+3.75 (+1.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
34.2K
Beta
0.62
Float Shares
5.48M
Free Float %
40.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.59% | +0.74% | +6.69% | -9.84% | -34.03% | -25.53% | -36.58% | -61.51% | -50.81% | -50.81% | -50.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
236.85
DCF (Unlevered)
21.88
-90.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
3.50
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+21.7% ★ Q1'26: +104.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+29.2% ★ Q1'26: +72.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-21.8% Q1'26: -24.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.3% Q1'26: +6.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.5% Q1'26: +4.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.1% Q1'26: -7.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.44× Q1'26: 2.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.12B
est: 1.12B (-0.5%)
|
1.23B
est: 1.30B (-6.0%)
|
1.26B
est: 1.44B (-12.6%)
|
1.13B
est: 1.65B (-31.8%)
|
1.63B
est: 1.12B (+45.1%)
|
1.12B
1.12B – 1.12B
+0.0% YoY
|
1.30B
1.30B – 1.30B
+16.4% YoY
|
1.44B
1.44B – 1.44B
+10.1% YoY
|
1.65B
1.65B – 1.65B
+15.0% YoY
|
| EBITDA |
186.70M
est: 193.22M (-3.4%)
|
206.74M
est: 224.96M (-8.1%)
|
214.11M
est: 247.74M (-13.6%)
|
204.25M
est: 284.90M (-28.3%)
|
201.02M
est: 174.80M (+15.0%)
|
174.80M
174.80M – 174.80M
+0.0% YoY
|
203.52M
203.52M – 203.52M
+16.4% YoY
|
224.13M
224.13M – 224.13M
+10.1% YoY
|
257.74M
257.74M – 257.74M
+15.0% YoY
|
| EBIT |
163.08M
est: 146.82M (+11.1%)
|
184.60M
est: 170.94M (+8.0%)
|
185.49M
est: 188.25M (-1.5%)
|
168.25M
est: 216.49M (-22.3%)
|
130.36M
est: 125.24M (+4.1%)
|
125.24M
125.24M – 125.24M
+0.0% YoY
|
145.81M
145.81M – 145.81M
+16.4% YoY
|
160.57M
160.57M – 160.57M
+10.1% YoY
|
184.66M
184.66M – 184.66M
+15.0% YoY
|
| Net Income |
101.13M
est: 123.61M (-18.2%)
|
120.26M
est: 147.88M (-18.7%)
|
132.91M
est: 156.77M (-15.2%)
|
121.29M
est: 186.88M (-35.1%)
|
71.08M
est: 129.93M (-45.3%)
|
129.93M
129.93M – 129.93M
+0.0% YoY
|
155.44M
155.44M – 155.44M
+19.6% YoY
|
164.79M
164.79M – 164.79M
+6.0% YoY
|
196.44M
196.44M – 196.44M
+19.2% YoY
|
| SGA |
59.56M
est: 124.66M (-52.2%)
|
47.25M
est: 145.14M (-67.4%)
|
52.57M
est: 159.84M (-67.1%)
|
95.99M
est: 183.82M (-47.8%)
|
321.98M
est: 152.85M (+110.6%)
|
152.85M
152.85M – 152.85M
+0.0% YoY
|
177.96M
177.96M – 177.96M
+16.4% YoY
|
195.98M
195.98M – 195.98M
+10.1% YoY
|
225.38M
225.38M – 225.38M
+15.0% YoY
|
| EPS |
9.03
est: 9.73 (-7.2%)
|
10.28
est: 11.64 (-11.7%)
|
10.88
est: 12.34 (-11.8%)
|
9.93
est: 14.71 (-32.5%)
|
5.59
est: 9.73 (-42.5%)
|
9.73
9.73 – 9.73
+0.0% YoY
|
11.64
11.64 – 11.64
+19.6% YoY
|
12.34
12.34 – 12.34
+6.0% YoY
|
14.71
14.71 – 14.71
+19.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-132.48M
OE per share TTM
-7.77
Owner's Yield
-4.15%
Maintenance CapEx ratio
28.03%
Maint CapEx / Avg PPE
58.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
327.2K
Shares Outstanding
13.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aneek Gupta | Head of Pharmacovigilance & Operations | — | — |
| Ashwani Kumar Sharma | Whole-Time Director | — | male |
| Chandan Kumar | Chief Financial Officer | — | male |
| Parul Choudhary | Compliance Officer & Company Secretary | — | female |
| Rajesh Madan Pharma | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEDICAMEQ.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
